Table 1.
# | MM subtype | BM infiltration | CG | Age (yrs) | Gender | Status | ISS | Comment |
---|---|---|---|---|---|---|---|---|
1 | IgA kappa | 80% | HR | 69 | Female | RRMM | 1 | MM |
2 | IgG kappa | 80% | HR | 70 | Male | RRMM | 2 | MM |
3 | kappa-LC | 80% | HR | 52 | Male | RRMM | 1 | PCL |
4 | IgG kappa | 80% | HR | 83 | Male | ID | 3 | MM |
5 | IgA kappa | 90% | HR | 66 | Male | RRMM | 3 | MM |
6 | IgG kappa | 90% | HR | 51 | Male | ID | 3 | MM |
Σ median (range) | IgG (n = 3) | 80% (80–90%) | HR (n = 6) | 68 (51–83) | Female (n = 1) | RRMM (n = 6) | 1 (n = 2) | MM (n = 5) |
IgA (n = 2) | Male (n = 5) | ID (n = 2) | 2 (n = 1) | PCL (n = 1) | ||||
kappa-LC (n = 1) | 3 (n = 3) |
MM multiple myeloma, RRMM relapsed/refractory MM, ID initial diagnosis, PCL plasma cell leukemia, EM-MM extramedullary MM, CG cytogenetics, HR unfavorable cytogenetics defined as deletion 17p, t(4;14), t(14;16), t(14;20) or gain 1q